Search Within

Dmitriy Zamarin

  1. "2022"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (19)
  3. Editorial (1)
Groups
  1. Department of Medicine (40)
  2. GDMT, Medicine (40)
  3. Gynecologic Medicine Service (40)
  4. Gynecology Disease Management Team (40)
  5. Solid Tumor Oncology Division (40)
  6. Sloan Kettering Institute Postdocs (22)

More Groups

People
  1. Britta Weigelt (16)
  2. Carol Aghajanian (13)
  3. Claire Friedman (12)
  4. Nadeem Abu-Rustum (11)
  5. Roisin O'Cearbhaill (8)
  6. Sohrab Shah (8)

More People

Years
  1. 2022 (40)
Publications
  1. Cancer Research (10)
  2. Gynecologic Oncology (6)
  3. Journal of Clinical Oncology (5)
  4. International Journal of Gynecological Cancer (3)
  5. Nature (3)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (12)
  2. American Society of Clinical Oncology (7)
  3. Elsevier Inc. (6)
  4. Nature Publishing Group (4)
  5. Lippincott Williams & Wilkins (3)
  6. Biomed Central Ltd (2)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • State of the biomarker dcience in ovarian cancer: A National Cancer Institute Clinical Trials Planning Meeting Report
    Journal Article

    Ethier, J. L.; Fuh, K. C.; Arend, R.; Konecny, G. E.; Konstantinopoulos, P. A.; Odunsi, K.; Swisher, E. M.; Kohn, E. C.; Zamarin, D.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Germline SMARCA4 deletion as a driver of uterine cancer: An atypical presentation
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Makker, V.; Weigelt, B.; Zamarin, D.; Liu, Y.; Arnold, A. G.; Chui, M. H.; Mandelker, D. L.; Walsh, M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
    Meeting Abstract

    Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
    Meeting Abstract

    Purroy, N.; Durham, N.; Phillips, M.; Hattersley, M. M.; Jung, L.; Davar, D.; Zamarin, D.; Johanns, T. M.; Puzanov, I.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Oldridge, D. A.; Wellhausen, N.; Greenplate, A. R.; Chilukuri, L.; Mathew, D.; Xu, C.; Herati, R. S.; Huang, A. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma
    Meeting Abstract

    O'Connor, C. M.; Taylor, S. E.; Miller, K. M.; Hurst, L.; Haanen, T. J.; Suhan, T. K.; Zawacki, K. P.; Noto, F. K.; Trako, J.; Mohan, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Defining the balance of anti-viral and anti-tumor T cell responses to oncolytic virus therapy using single cell approaches
    Meeting Abstract

    Burman, B.; Ceglia, N.; Hirschhorn, D.; Budhu, S.; Mangarin, L.; Oseledchyk, A.; Bykov, Y.; McPherson, A.; Shah, S.; Wolchok, J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes
    Meeting Abstract

    Vázquez-García, I.; Uhlitz, F.; Ceglia, N.; Lim, J. L.; Wu, M.; Mohibullah, N.; Ruiz, A. E. B.; Boehm, K. M.; Bojilova, V.; Fong, C. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save